Fig 1.
Anti-Norovirus salivary IgG response at S2 measured as median fluorescence intensity.
(a) Anti-Norovirus GI.1 salivary IgG response at S2, cubic spline (5 knot) function of age, and age-specific upper 75% prediction interval. The term “Positive” is used to denote individuals who immunoconverted and the term “Negative” for individuals who did not immunoconvert. (b) Anti-Norovirus GII.4 salivary IgG response at S2, cubic spline (5 knot) function of age, and age-specific upper 75% prediction interval. The term “Positive” is used to denote individuals who immunoconverted and the term “Negative” for individuals who did not immunoconvert.
Fig 2.
MFI ratios of salivary IgG responses to NoV at S2 (10–14 days) and S3 (30–40 days) to baseline (S1).
(a) GI.1 NoV IgG ratios to S1 for those who met immunoconversion criteria (blue lines) and a random sample (N = 30) of those who did not (orange lines). Solid horizontal line is shown at minimum S2/S1 ratio of four. The term “Positive” is used to denote individuals who immunoconverted and the term “Negative” for individuals who did not immunoconvert. (b) GII.4 NoV IgG ratios to S1 for those who met immunoconversion criteria (blue lines) and a random sample (N = 30) of those who did not (orange lines). Solid horizontal line is shown at minimum S2/S1 ratio of four. The term “Positive” is used to denote individuals who immunoconverted and the term “Negative” for individuals who did not immunoconvert.
Table 1.
Factors associated with NoV immunoconversionsa.
Table 2.
NoV immunoconversions and swimming exposures.
Table 3.
Risk factors for NoV immunoconversion- logistic regression models.